Silva Pharmaceuticals's earnings have been declining at an average annual rate of -70.8%, while the Pharmaceuticals industry saw earnings growing at 2.2% annually. Revenues have been declining at an average rate of 16.6% per year.
Key information
-70.82%
Earnings growth rate
-70.81%
EPS growth rate
Pharmaceuticals Industry Growth
11.00%
Revenue growth rate
-16.56%
Return on equity
-7.66%
Net Margin
-46.78%
Last Earnings Update
31 Mar 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Silva Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DSE:SILVAPHL Revenue, expenses and earnings (BDT Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
330
-154
227
0
31 Dec 25
357
-145
225
0
30 Sep 25
371
-136
219
0
30 Jun 25
384
-133
222
0
31 Mar 25
432
-132
229
0
31 Dec 24
498
-107
225
0
30 Sep 24
547
-90
218
0
30 Jun 24
600
-64
210
0
31 Mar 24
612
-31
200
0
31 Dec 23
638
-28
197
0
30 Sep 23
671
0
192
0
30 Jun 23
717
33
186
0
31 Mar 23
745
57
177
0
31 Dec 22
749
78
176
0
30 Sep 22
760
89
174
0
30 Jun 22
779
102
175
0
31 Mar 22
805
119
181
0
31 Dec 21
793
115
179
0
30 Sep 21
788
112
177
0
30 Jun 21
799
120
172
0
31 Mar 21
780
116
153
0
31 Dec 20
776
118
153
0
30 Sep 20
788
126
150
0
30 Jun 20
763
119
158
0
31 Mar 20
769
126
164
0
31 Dec 19
767
133
153
0
30 Sep 19
756
131
150
0
30 Jun 19
732
143
144
0
31 Mar 19
725
136
136
0
31 Dec 18
707
125
132
0
30 Sep 18
695
123
129
0
30 Jun 18
685
93
128
0
31 Mar 18
687
100
126
0
30 Jun 17
602
80
114
0
30 Jun 16
586
70
88
0
Quality Earnings: SILVAPHL is currently unprofitable.
Growing Profit Margin: SILVAPHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SILVAPHL is unprofitable, and losses have increased over the past 5 years at a rate of 70.8% per year.
Accelerating Growth: Unable to compare SILVAPHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SILVAPHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.5%).
Return on Equity
High ROE: SILVAPHL has a negative Return on Equity (-7.66%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/13 23:43
End of Day Share Price
2026/06/11 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silva Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.